MCM
RCUS icon

MAI Capital Management’s Arcus Biosciences RCUS Stock Holding History

MAI Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238 Buy
+11
New +$238 ﹤0.01% 4584
2025
Q3 		– Sell
-242
Closed -$1.97K – 4076
2025
Q2 		$1.97K Buy
+242
New +$2.07K ﹤0.01% 3426

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

MAI Capital Management's RCUS Position: Q1 2026 in Review

MAI Capital Management opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 11 shares worth $238. The stake represents ﹤0.01% of the portfolio and ranks #4584 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in RCUS as recently as Q2 2025.

MAI Capital Management first reported a position in RCUS in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.97K in Q2 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • MAI Capital Management held 11 shares of Arcus Biosciences worth $238 as of Q1 2026.
  • Arcus Biosciences was a new MAI Capital Management position in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4584 holding.
  • MAI Capital Management first reported a position in Arcus Biosciences in Q2 2025 and has held it in 2 quarters since.
  • MAI Capital Management's Arcus Biosciences position peaked at $1.97K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.